Biotech | December 24, 2021
Lecanemab granted Fast Track designation by the U.S. FDA
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
Theradaptive's regenerative implants are best-in-class and are designed to permit precise tissue regeneration for a variety of tissue types and clinical indications
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
The first clinical trial is expected to commence in early 2022 both in Europe and the US
It will also manage test result documentation for employees who are not vaccinated, sending weekly reminders and employer notification
The document is a global recommendation for circular packaging design. It will be updated and adapted to changes in the collection, sorting and recycling technology, as well as to future material development
Subscribe To Our Newsletter & Stay Updated
